Liposomal anthracyclines for breast cancer.

[1]  A. Wolff,et al.  Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[3]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Tzemach,et al.  Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.

[5]  E. Winer,et al.  Phase I study of Doxil and vinorelbine in metastatic breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  D. Tzemach,et al.  Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.

[7]  G. Hortobagyi,et al.  Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Shapiro,et al.  Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[10]  J. Sparano.  Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. , 1998, Seminars in oncology.

[11]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[12]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Torti,et al.  The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Tzemach,et al.  Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Stewart,et al.  Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Howell,et al.  Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Harrington,et al.  The Biodistribution and Pharmacokinetics of Stealth Liposomes in Patients with Solid Tumors , 1997 .

[18]  G. Bonadonna,et al.  Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Swain,et al.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Northfelt,et al.  Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma , 1997, Clinical pharmacology and therapeutics.

[21]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Gehl,et al.  Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. , 1996, Seminars in oncology.

[23]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Volberding,et al.  Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.

[25]  A. Gabizon,et al.  Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. , 1995, Journal of neurosurgery.

[26]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Working,et al.  Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts , 1994, Cancer.

[28]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[29]  E. Mayhew,et al.  Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes , 1993, Cancer.

[30]  F. Martin,et al.  Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. , 1993, Cancer research.

[31]  S. Ebbs,et al.  Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. , 1993, British Journal of Cancer.

[32]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[33]  D. Lasič,et al.  Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes , 1992, International journal of cancer.

[34]  L. Norton,et al.  A phase I-II study of intensive-dose adriamycin for advanced breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  F. Rosato,et al.  Diseases of the Breast , 1972 .

[36]  Z. Pavelic,et al.  Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. , 1993, In vivo.

[37]  Z. Pavelic,et al.  Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. , 1993, In vivo.

[38]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[39]  A. Bangham,et al.  NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. , 1964, Journal of molecular biology.